

## PRESS RELEASE

FOR: CARDIOCOMM SOLUTIONS, INC.

TSX VENTURE SYMBOL: EKG

May 9, 2012

# CARDIOCOMM SOLUTIONS FEATURED AS A PREFERRED PROVIDER FOR EXPANSION INTO THE WIRELESS CARDIAC MONITORING MARKET IN THE USA AT THE HEART RHYTHM SOCIETY MEETING IN BOSTON.

CardioComm Solutions' Novel Wireless and WEB Based ECG Management Software will be the Heart of Wireless Arrhythmia Services in the USA

**Toronto, Canada.** – CardioComm Solutions, Inc. (TSX-V:EKG) ("CardioComm Solutions" or the "Company") today announced the limited release of its new proprietary GEMS<sup>™</sup> Air software, electrocardiogram ("ECG") SDK viewer (GUAVA<sup>™</sup>) and a new customized web-based device interface. The pre GEMS<sup>™</sup> 4.0 version will be incorporated into wireless arrhythmia services for the remote diagnostic arrhythmia and remote patient monitoring market.

The new GEMS<sup>TM</sup> Air software solution was designed to simplify the work flow associated with real-time, wireless cardiac monitoring. While broad commercial release of GEMS<sup>TM</sup> 4.0 is scheduled for later this year, Philips Healthcare and TZ Medical have leveraged this limited advanced version of the software, along with its customized web-based device interface, in their remote diagnostic arrhythmia monitoring technology and services. Both companies will each separately announce their product debuts during the Heart Rhythm 2012 Annual Scientific Sessions in Boston, MA.

"CardioComm Solutions is continuing to strengthen its alliances with many Tier 1 health service leaders," said Dr. Anatoly Langer, Chairman of CardioComm Solutions' Board. "Our ongoing work with international medical technology companies is a critical part of this long term strategy. This newest of our GEMS<sup>TM</sup> based software technology advances is already of significant interest to medical companies that possess large global sales and marketing networks and that possess, or can access, existing relationships with the world's cardiologists, hospitals and monitoring services," Dr. Langer added.

"For the past three years CardioComm Solutions has been compiling new GEMS<sup>™</sup> and GUAVA<sup>™</sup> solutions to enable the integration of multiple ECG recording and transmitting devices that have received FDA market clearance, Health Canada Medical Device Licensure, as well as the European CE Mark for medical devices. This release marks another important milestone in achieving that objective," noted Etienne Grima, Chief Executive Officer of CardioComm Solutions. "CardioComm Solutions continues to demonstrate that we are an innovative solutions provider that meets the business and medical care challenges associated with the growing ECG monitoring markets."

"CardioComm Solutions has developed the most advanced connectivity option between device and medical call centre. Their GEMS<sup>TM</sup> software is the engine behind the launch of the AERA CT mobile Cardiac telemetry (MCT) device and will be part of the international marketing efforts of TZ Medical," stated John Lubisich, President, TZ Medical, Inc.

"CardioComm Solutions has worked with Philips as a preferred provider of ECG interfaces and management tools for many years within the cardiac monitoring service environment," said Martha Dolan, Marketing Director, Philips Remote Cardiac Services. "With their logical approach to solutions development and their on-time business delivery, CardioComm Solutions has proven to be a reliable provider in support of our goal to improve the lives of our patients."

The global Cardiovascular Monitoring and Diagnostic devices market is forecast to reach US\$12 billion by 2015 with the North American segment accounting for approximately 40%, Europe more than 25% and Asia-Pacific as the fastest growing region driving a value of US\$3.4 billion. "These early start US based strategic relationships highlight the opportunities that can be replicated in Canada, South America and overseas by leveraging CardioComm Solutions' multi-country client base," adds Mr. Grima.

#### **About CardioComm Solutions**

CardioComm Solution's patented and proprietary technology is used in products for recording, viewing,



analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.

FOR FURTHER INFORMATION PLEASE CONTACT: Etienne Grima, Chief Executive Officer 1-877-977-9425 egrima@cardiocommsolutions.com www.cardiocommsolutions.com

### **Forward-Looking Statements**

This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release